A Director at Emergent Biosolutions is Exercising Options


Today it was reported that a Director at Emergent Biosolutions (EBS), Sue Bailey, exercised options to sell 17,717 EBS shares at $16.32 a share, for a total transaction value of $1.23M.

Following Sue Bailey’s last EBS Sell transaction on March 13, 2009, the stock climbed by 55.9%. In addition to Sue Bailey, 3 other EBS executives reported Sell trades in the last month.

See today’s analyst top recommended stocks >>

Based on Emergent Biosolutions’ latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $174 million and quarterly net profit of $20.95 million. In comparison, last year the company earned revenue of $149 million and had a net profit of $33.55 million. EBS’s market cap is $3.63B and the company has a P/E ratio of 36.97. Currently, Emergent Biosolutions has an average volume of 443.4K.

Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $73.50, reflecting a 2.6% upside.

The insider sentiment on Emergent Biosolutions has been negative according to 58 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures that address public health and national security threats. It includes Chemical, Biological, Radiological, Nuclear and Explosive or CBRNE threats; as well as emerging infectious diseases.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts